Majority of DVT Cases Treated in Single-Setting With Trellis-8 Catheter
From Bacchus Vascular, Reducing Patient Lytic Exposure, Bleeding
Complications and Treatment Cost
SANTA CLARA, Calif., March 6 /PRNewswire/ -- Bacchus Vascular Inc., a leading provider of innovative medical devices used by interventional radiologists, vascular surgeons and interventional cardiologists for the minimally invasive treatment of deep vein thrombosis (DVT) and other peripheral vascular disease, announced today that the Journal of Vascular Interventional Radiology (JVIR) has published a study comparing the clinical use of the Trellis-8 infusion catheter from Bacchus Vascular with conventional catheter-directed thrombolysis (CDT) in the treatment of DVT in its March 2008 issue.
Results of the study showed that Grade II and III lysis was achieved in 93% of patients treated with the Trellis catheter and 79% of patients treated with CDT even though thrombolytic doses and infusion durations were less with the Trellis catheter than with conventional CDT. Major hemorrhage was reported in none of the Trellis catheter patients and in 8.5% of patients treated with CDT. The per-patient cost of therapy was $3,697 for the Trellis catheter and $5,473 for CDT. This cost reduction is due to approximately 80% of the Trellis catheter patients being treated in the single-setting of the interventional suite with less time required for follow-up monitoring in a costly critical care unit compared with CDT patients.
The study, which was authored by Daniel E. Hilleman, PharmD (Department of Pharmacy Practice, Creighton University School of Pharmacy, Omaha, NE) and Mahmood K. Razavi, MD (Department of Vascular and Interventional Radiology, Stanford University Hospital, Stanford, CA), compared retrospectively collected data from 147 patients treated for DVT with the Trellis-8 infusion catheter at 45 hospitals in the U.S. and three hospitals outside the U.S. with a meta-analysis of 14 published studies in the medical literature in which CDT was performed on a minimum of 15 patients with DVT.
"We are gratified to see this rigorously-analyzed comparative data published in a major medical journal," stated Scott Cramer, President and CEO of Bacchus Vascular. "We continue to believe in both the strong clinical and economic utility of the Trellis infusion catheter as recognition increases in the medical community of the benefit of early DVT intervention in combating post-thrombotic syndrome and potential future DVT events."
About Bacchus Vascular
Bacchus Vascular, Inc. is a privately held medical device company dedicated to the treatment of peripheral vascular disease. Dr. Thomas Fogarty, a noted inventor and cardiovascular surgeon, founded the company with the vision of transforming blood clot removal from peripheral blood vessels into a fast, simple, minimally-invasive catheter-based procedure. Thousands of patients suffering from DVT and other occlusive vascular diseases have been treated worldwide to date using the company's Trellis(R) Peripheral Infusion System and other products.
For more information, visit http://www.bacchusvascular.com.
|SOURCE Bacchus Vascular Inc.|
Copyright©2008 PR Newswire.
All rights reserved